BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20190101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20190101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200206
DTEND;VALUE=DATE:20200208
DTSTAMP:20260515T051839
CREATED:20191031T095454Z
LAST-MODIFIED:20191031T104545Z
UID:23112-1580947200-1581119999@www.pharmajournalist.com
SUMMARY:4th Edition MarketsandMarkets Genome Editing & Gene Therapy Conference
DESCRIPTION:Since our past editions we dedicated our focus on the latest developments and addressed various applications of CRISPR as a molecular tool\, gene expression\, knock-in\, genomic screening\, along with therapeutic developments through animal modeling. Attended by 100+ genome editing professionals and 20+ gene expert speakers\, the event saw participation of big companies like Casebia Therapeutics\, Genentech\, BMS\, Cellectis \, University of Laval\, University of California\, Center of Advanced Genome Engineering\, Georgia Tech\, Stanford University\, Locana\, Harvard Medical School\, Agility\, Poseida\, Vertex\, Ligandal\, Integrated DNA Technologies\, GE Healthcare\, Cellecta\, Agilent\, Advanced Analytical\, Thermofisher\, Atum\, Synthego\, New England Biolabs\, Aldevron\, Applied Stem Cell and more. \n \nIn 2020\, coming with the 4th Edition MarketsandMarkets Genome Editing & Gene Therapy Conference on 6th & 7th February in San Diego\, we are getting ahead by discussing the commercialization and advancements of technology which will outline breakthrough advancements in pre-clinical & clinical therapeutics using genome Editing. The event will also focus on analysis of off target effects\, specificity and aspects of gene and cellular therapies. \nTo learn more about 4th Edition MarketsandMarkets Genome Editing & Gene Therapy Conference click here
URL:https://www.pharmajournalist.com/event/4th-edition-marketsandmarkets-genome-editing-gene-therapy-conference/
LOCATION:San Diego\, CA
ORGANIZER;CN="MarketsandMarkets Research Private Ltd.":MAILTO:suraj.waghmare@marketsandmarkets.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200206
DTEND;VALUE=DATE:20200208
DTSTAMP:20260515T051839
CREATED:20191031T101817Z
LAST-MODIFIED:20191031T101817Z
UID:23125-1580947200-1581119999@www.pharmajournalist.com
SUMMARY:5th Annual MarketsandMarkets Biomarker and Companion Diagnostics Conference
DESCRIPTION:The 5th Annual Biomarker and Companion Diagnostics Conference scheduled to be held on 6th – 7th February 2020 in San Diego\, CA would address the gaps between early stage biomarker development and the commercialization stage of biomarkers. This conference would also highlight case studies on leveraging emerging technologies in Digital Biomarkers\, Precision Medicine and Big Data. Regarding commercialization of biomarkers\, leading industry and academic experts would share their case studies focusing on advancements in companion diagnostics area. The keynote presentations would also help the attendees understand the issues related to clinical translation of biomarkers. \n \nTo learn more about 5th Annual Biomarker and Companion Diagnostics Conference click here
URL:https://www.pharmajournalist.com/event/5th-annual-marketsandmarkets-biomarker-and-companion-diagnostics-conference/
ORGANIZER;CN="MarketsandMarkets Research Private Ltd.":MAILTO:Shardul.oza@marketsandmarkets.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200206
DTEND;VALUE=DATE:20200208
DTSTAMP:20260515T051839
CREATED:20191031T102512Z
LAST-MODIFIED:20191031T104231Z
UID:23129-1580947200-1581119999@www.pharmajournalist.com
SUMMARY:MarketsandMarkets Gen-Next Probiotics and Microbiome Congress
DESCRIPTION:What are the essentials being missed out on? What is the real role of probiotics strains\, prebiotics and symbiotic in influencing a health? How do you standardize microbiome analysis? \nWitness the major breakthroughs of microbiome\, probiotics and prebiotics research along with their applications pertaining to challenges like medicinal data interpretation\, investment and regulatory hurdles faced by the practitioners. The intersection between emerging technology and discovery with the context of consumer interest. Detect the non-identified dysbiosis\, to discover the potential areas under study for investments in Gut and Skin microbiome and its role as a diagnostic tool of pharmaceutical discovery. \n \nJoin us at Gen-Next Probiotics and Microbiome Congress\, 2020 to network with biotech\, pharma\, academicians and investors to exchange views and observe the most ingenious research and technologies. Understand what’s happening. Witness the amalgamation of study focused on pharmaceutical and medicinal approaches of probiotics and the nutraceutical and consumer approaches along with the role of microbiome in clinical applications and preventative medicine. \nTo learn more about MarketsandMarkets Gen-Next Probiotics and Microbiome Congress click here
URL:https://www.pharmajournalist.com/event/marketsandmarkets-gen-next-probiotics-and-microbiome-congress/
LOCATION:San Diego\, CA
ORGANIZER;CN="MarketsandMarkets Research Private Ltd.":MAILTO:suraj.waghmare@marketsandmarkets.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200217
DTEND;VALUE=DATE:20200219
DTSTAMP:20260515T051839
CREATED:20200109T074622Z
LAST-MODIFIED:20200109T074622Z
UID:23582-1581897600-1582070399@www.pharmajournalist.com
SUMMARY:Smartlab Exchange Europe
DESCRIPTION:The Smartlab Exchange is an invitation-only meeting bringing together 70 of the most senior lab leaders from across Europe\, plus a number of hand-selected solution providers for two days of one-to-one business meetings\, benchmarking\, discussions and networking. \n \nKey themes include: \n✓ Devising a Roadmap to Success for an Agile\, Adaptable\, Digitised Lab\n✓ Leveraging Big Data Analytics and Informatics\n✓ Embedding a Culture of Collaboration and Innovation\n✓ Enhancing Visibility Across Existing Systems/Processes and Integrate Emerging Technologies\n✓ Implementing Methods to Safeguard Data Integrity and Uphold Regulatory Compliance \n96% of our attendees would recommend our event \n“I got more out of one day at Smartlab than a normal day at another conference.” –  R&D IS Program Manager\, Biomerieux \nBelow are some of the 20+ presentations and interactive sessions we have in store: \n\nNovartis – Exploring Data Visualisation Software To Increase The Accuracy Of Your Predictions\nRoche – Connecting Your Instruments For Easy Data Access And Analysis Across Your Lab\nJanssen – The Lab Of The Future: Predicting How The Lab Will Develop In the Next 5 Years\nUCB – Developing Your Data Capture Process For Increased Efficiency\n\nCheck out the full agenda here: http://bit.ly/2T75ps7
URL:https://www.pharmajournalist.com/event/smartlab-exchange-europe/
LOCATION:Hotel Palace Berlin\, Germany
ORGANIZER;CN="IQPC":MAILTO:info@exchangeevents.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200218
DTEND;VALUE=DATE:20200221
DTSTAMP:20260515T051839
CREATED:20191017T094701Z
LAST-MODIFIED:20191017T094701Z
UID:22911-1581984000-1582243199@www.pharmajournalist.com
SUMMARY:Disposable Solutions for Bio Manufacturing
DESCRIPTION:Now in it’s 12th year\, the 2020 Disposable Solutions for Biomanufacturing Forum is the only global forum that focuses on the use of disposable products and single use systems in biomanufacturing. Our attendees will be guided through their journey and understand how they can run 100% disposable sites and scale their manufacturing capabilities with our newly designed program focused on implementation\, systems management and future technology. \n \nThe three packed days will consist of case studies and interactive sessions to identify new technologies\, determine how to approach automated systems\, transition to continuous processes and learn how to implement best practice in system testing & life cycle management! \nTo learn more about Disposable Solutions for Bio Manufacturing and to register online\, visit http://bit.ly/2Mp6lEs
URL:https://www.pharmajournalist.com/event/disposable-solutions-for-bio-manufacturing/
LOCATION:Leonardo Royal Hotel Berlin Alexanderplatz\, Berlin\, Germany\, Germany
ORGANIZER;CN="IQPC":MAILTO:enquire@iqpc.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200219
DTEND;VALUE=DATE:20200221
DTSTAMP:20260515T051839
CREATED:20171019T063951Z
LAST-MODIFIED:20191004T082421Z
UID:3496-1582070400-1582243199@www.pharmajournalist.com
SUMMARY:RNA Therapeutics
DESCRIPTION:SMi Group are pleased to present the 11th Annual RNA Therapeutics Conference and Focus Day in London on February 18th – 20th 2020. \nThe field of RNA therapeutics is rapidly expanding\, and the potential for using RNA drugs for personalised medicines and immunotherapy\, as well as to address genetic\, infectious and chronic diseases will ensure the continued development of RNA therapeutics for years to come. \n \nThe event will focus on the latest research and developments on delivery system technologies that aim to tackle more difficult targets within the human body. This overarching topic warrants high focus and therefore\, for the first time in the series\, introduce a focus day on Oligonucletide Delivery Systems. The main conference will focus on current developments in the area of mRNA therapeutics in immunotherapy and vaccination. \nNEW FOR 2020: RNA Therapeutics Focus Day – Oligonucleotide Delivery Systems \nIntroducing the only RNA therapeutics conference to hold a full day exploring alternatives to oligonucleotide delivery systems. The global antisense and RNA therapeutics market is expected to expand at a compound annual growth rate (CAGR) of 8.6% between 2019 and 2025\, projected to reach $1.81 billion\, this focus day will assess the growing need for research and development of novel delivery approaches to expand the current delivery methods in today’s market. \nHow will you benefit? \n\nDiscuss the innovations in oligonucleotide delivery systems\nExplore the latest developments in RNA delivery agents and RNA-based therapeutics\nLearn from case studies on clinical developments with leading RNA therapeutics companies and regulatory bodies\nRevisit the challenges for clinical translation of RNA-based therapeutics\nEvaluate the applications of RNA-based drugs for modulation of gene and protein expression\, and genome editing\nGain an expert view on new and upcoming regulatory updates and industry implications\n\nNetwork and learn from leading professionals such as: \nCHAIR FOR 2020 \nHeinrich Haas\, VP RNA Formulation and Drug Delivery\, BioNTech \nFEATURED SPEAKERS INCLUDE: \n\nShalini Andersson\, Chief Scientist New Therapeutic Modalities\, AstraZeneca\nChristian Plank\, CTO\, Ethris\nSteve Pascolo\, Founder and CEO\, Miescher Pharma\nKirsty Wydenbach\, Deputy Unit Manager\, Clinical Trials Unit\, MhRA\nSteven Powell\, CEO\, eTheRNA\nSimon Newman\, CSO\, Nanogenics\nChristiane Niederlaender\, Director\, AMBR Consulting and Formerly\,\nQuality Assessor\, Biologicals\, MhRA\nKlaus Giese\, CEO\, Pantherna Therapeutics\nDavid Blakey\, CSO\, MiNA Therapeutics\nJeffrey Ulmer\, Head Preclinical R&D\, GSK\n\nFor more information and to register\, visit: www.therapeutics-rna.com/pjwb  \nEarly-Bird Rates \nREGISTER BY 31ST OCTOBER TO SAVE £400 \nREGISTER BY 29Th NOVEMBER TO SAVE £200 \nREGISTER BY 13Th DECEMBER TO SAVE £100 \nSocial Media Handles \nFollow us on LinkedIn ‘SMi Pharma’\, Twitter @SMiPharm and use #SMiRNA
URL:https://www.pharmajournalist.com/event/rna-therapeutics/
LOCATION:London\, UK\, United Kingdom
ORGANIZER;CN="SMi Group Ltd":MAILTO:nhoward@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200219
DTEND;VALUE=DATE:20200221
DTSTAMP:20260515T051839
CREATED:20191015T105531Z
LAST-MODIFIED:20191015T105531Z
UID:22854-1582070400-1582243199@www.pharmajournalist.com
SUMMARY:SMi’s 4th Annual 3D Cell Culture
DESCRIPTION:CHAIRED BY:\nPhilip Hewitt\, UK and Eurotox Registered Toxicologist\, Global Head of Early Investigative Toxicology\, Merck Healthcare KGaA\nStefan Przyborski\, Professor of Cell Technology\, Durham university \nDevelopment and application of human organs and tissues in vitro\nOver the past few years\, 3D Cell Culture has gained momentum within the pharmaceutical industry due to the benefits that this model offers for in vitro applications patient-derived tissues\, drug discovery\, predictivity and validation\, and safety and toxicity.\n\nSMi’s 3D Cell Culture Conference will explore advances of organ and lab-on-a-chip\, microphysiological systems\, applications of technology and case studies\, imaging\, high throughput screening and advances in 3D cell culture models which make up core components within the 3D Cell Culture field. \nBioprinting has become increasingly efficient and accurate in building in vitro tissue models with the potential to provide pathologically relevant responses and model human disease mechanisms. Bio-printed structures yield phenotypic endpoints that are comparable with clinical studies and can provide a realistic prediction of clinical efficacy. The use of bioprinting is growing in big pharma companies as an alternative to organ-on-a-chip systems. \nFor the first time ever the NEW 3D Bioprinting Focus Day on 18 February 2020 will explore case studies from big pharma\, biotech’s and academia exploring how bioprinting is being used in industry highlighting projects looking at stem cell therapy\, drug screening and extracellular matrix scaffolds. \nEvent Hashtag: #SMi3DCellCulture \nFEATURED SPEAKERS INCLUDE: \n\nLeonard Both\, Senior Quality Assessor\, Biologicals/Biotechnology Unit\, MHRA\nVeronique Barban\, Expert Virology\, Research and Nonclinical Safety Department\, Sanofi Pasteur\nSimone Stahl\, Associate Principal Scientist\, ADME Sciences\, Clinical Pharmacology and Safety Sciences\, AstraZeneca\nWendy Rowan\, Scientific Director\, Novel Human Genetics Research Unit\, GSK\nJason Ekert\, Head of Complex In Vitro Models\, GSK\nSamuel Jackson\, Programme Manager\, Disease Models Efficacy and Safety Pharmacology\, NC3RS\n\nKEY TOPICS FOR 2019 INCLUDE: \n\nLearn from leading pharma companies to benchmark against their applications of 3D technology\nExplore case studies of 3D cell culture\, high throughput screening\, imaging and microphysiological systems in industry\nHear about the latest technology advances allowing 3D bioprinting to revolutionise in vitro models\nDiscuss organ-on-chip technologies and their applications to replace the use of animals in pharmaceutical research\nParticipate in a panel discussion on adopting new technologies for 3D models\n\nView the full agenda: http://www.3d-cellculture.com/PJWL \nWHO SHOULD ATTEND? \nBiotech / Pharma Companies – Team Leader\, Junior Principle investigator\, Cell and Molecular Scientist\, Chief Scientific Officer\, Deputy Director\, Manager\, Founder\, CEO\, Head\, Director\, Programme Manager\, Lab Head\, Toxicologist \nAcademia Professor – Cell Technology\, Stem Cell Sciences\, Biochemistry\, Protein Technology and Tissue Engineering \nSolution Providers – Manager\, Head of\, CEO\, Director\, Founder\, Account Manager\, President\, CSO\, Executive\, Managing Director\, Vice President\, COO \nOrganisations / Regulatory – Director\, Senior Science Advisor\, Scientific Officer \nEARLY BIRD-RATES \n\nREGISTER BY 31ST OCTOBER AND SAVE £400\nREGISTER BY 29TH NOVEMBER AND SAVE £200\nREGISTER BY 13TH DECEMBER AND SAVE £100
URL:https://www.pharmajournalist.com/event/smis-4th-annual-3d-cell-culture/
LOCATION:Copthorne Tara Hotel\, London\, UK\, United Kingdom
ORGANIZER;CN="SMi Group":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200224
DTEND;VALUE=DATE:20200228
DTSTAMP:20260515T051839
CREATED:20191016T074751Z
LAST-MODIFIED:20191017T085729Z
UID:22867-1582502400-1582847999@www.pharmajournalist.com
SUMMARY:CAR-TCR Europe Summit
DESCRIPTION:With CAR-T therapies on the cusp of achieving global approval\, there are still many bottlenecks that are preventing this from becoming the ‘sell-out’ therapy that the field had hoped for. The CAR-TCR Europe Summit will unravel the technical challenges across translation\, scale and delivery to provide your team with the platform to learn\, collaborate and gain actionable insights to advance your therapy for clinical and commercial success. \nThis focused agenda will delve into the technical bottlenecks encountered in every stage of the CAR-TCR drug development cycle\, providing a comprehensive analysis across 3 tracks including: Translational\, Manufacturing & Clinical \nTo learn more about CAR-TCR Europe Summit and to register online\, visit https://ter.li/9iuqer
URL:https://www.pharmajournalist.com/event/car-tcr-europe-summit/
LOCATION:Novotel London West\, Hammersmith\, London\, W6 8DR
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200225
DTEND;VALUE=DATE:20200228
DTSTAMP:20260515T051839
CREATED:20191016T073714Z
LAST-MODIFIED:20191017T085556Z
UID:22862-1582588800-1582847999@www.pharmajournalist.com
SUMMARY:3rd Antigen Specific Immune Tolerance Summit
DESCRIPTION:Translating Emerging Antigen Specific Immune Tolerance Approaches for Therapeutic Applications \nAccelerate the progression of ethical and effective antigen specific immunotherapies through the clinic\, optimize the discovery of novel targets and explore novel therapeutic approaches harnessing combination therapies. \n \nBuilding on the success of the 2019 meeting\, the 3rd Antigen Specific Immune Tolerance Summit (ASIT) returns to Boston on February 25-27\, 2020. The meeting will bring together industry representatives from the fields of autoimmunity\, allergy\, immuno-oncology and transplantation to tackle the complexities behind autoimmune disorders head on. With momentum building for antigen specific immunotherapies\, ASIT 2020 is the only antigen specific summit offering thought leading content to drive the field towards a more precise and ethical antigen-specific approach to drug development. \n\nHear from and engage with a world-class speaking faculty made up of 26 industry representatives including Novo Nordisk\, Pfizer\, Merck\, Eli Lilly\, ITN & FDA\nExplore cross learning opportunities from parallel fields tackling immune tolerance and better understand the fundamental mechanisms that lie behind tolerance induction\nEngage with and immerse yourself within a learning journey across three conference days\, tackling all elements of drug development from discovery to clinical development\nGain practical insight from those describing recent clinical trials and determine what mechanisms lie behind successful and unsuccessful clinical trials\nEmploy novel therapeutics in combination with antigen specific immunotherapies and drive the progression of drug development towards the clinic\nTake advantage of intimate networking opportunities with key opinion leaders from large pharma\, biotech and academia through discursive and engaging platforms that spark conversation and debate\n\nTo learn more about 3rd Antigen Specific Immune Tolerance Summit and to register online\, visit https://ter.li/rp07a3
URL:https://www.pharmajournalist.com/event/3rd-antigen-specific-immune-tolerance-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200225
DTEND;VALUE=DATE:20200228
DTSTAMP:20260515T051839
CREATED:20191215T123515Z
LAST-MODIFIED:20191215T123645Z
UID:23340-1582588800-1582847999@www.pharmajournalist.com
SUMMARY:RAS- Targeted Drug Discovery Summit Europe
DESCRIPTION:After three decades of trial and error to target the driver of 30% of all diagnosed cancers\, scientists are finally making meaningful clinical progression to target the cancer master switch\, the RAS family of proteins. \n \nThe RAS- Targeted Drug Discovery Summit Europe is the only industry-led and translational focused platform dedicated to bringing you innovative anti-RAS drug discovery science\, capturing the most pioneering data\, thought-provoking insights and practical lessons learned\, enabling you to maximise the clinical therapeutic window of your anti-RAS candidate. With numerous approaches emerging that demonstrate genuinely viable efficacy in targeting the RAS family of proteins\, gain first-hand insights on the challenges and strategies to robustly translate promising anti-RAS therapies into the clinic. Hear from the likes of Boehringer Ingelheim\, Sanofi\, Bayer\, Francis Crick Institute\, PhoreMost\, Allinky Biopharma\, Elicio Therapeutics\, Oblique Therapeutics\, Onconova Therapeutics and Revolution Medicines. Visit the website to see the full speaker line-up\, what will be discussed\, pricing and ticket options: https://ter.li/8qb2rr.
URL:https://www.pharmajournalist.com/event/ras-targeted-drug-discovery-summit-europe/
LOCATION:Hilton Vienna Plaza\, Schottenring 11\, Vienna\, A - 1010\, Austria
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200225
DTEND;VALUE=DATE:20200228
DTSTAMP:20260515T051839
CREATED:20200110T081422Z
LAST-MODIFIED:20200110T081422Z
UID:23647-1582588800-1582847999@www.pharmajournalist.com
SUMMARY:8th Neurodegenerative Drug Development Summit
DESCRIPTION:Returning to Boston in February 2020 is the 8th Neurodegenerative Drug Development Summit\, previously World CNS. \nDespite the lack of clinical trial success\, new investments are being made in forward-thinking biotechs\, digital and blood-based biomarker technologies are advancing\, new targets are emerging\, and gene therapy is taking the limelight. \nThe Neurodegenerative Drug Development Summit will unite industry stakeholders to learn how to overcome their translational challenges\, share their progress and network for future collaborations to accelerate the development of successful neurodegenerative therapeutics. \nDon’t miss your opportunity to join over 150 fellow CNS experts from Biogen\, AbbVie\, Sanofi and more\, and immerse yourself in the neurodegenerative community to help refresh the neurodegenerative approach and challenge traditional thinking to advance clinical progress.
URL:https://www.pharmajournalist.com/event/8th-neurodegenerative-drug-development-summit/
LOCATION:Hyatt Regency Boston\, 1 Avenue de Lafayette\, Boston\, MA\, 02111\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200226
DTEND;VALUE=DATE:20200228
DTSTAMP:20260515T051839
CREATED:20200217T092303Z
LAST-MODIFIED:20200217T092639Z
UID:24192-1582675200-1582847999@www.pharmajournalist.com
SUMMARY:21st Pharmacovigilance 2020
DESCRIPTION:“Latest developments in pharmacovigilance\, drug safety and RMP” \n21st Pharmacovigilance 2020 event keeps an immersed eye on discussion of critical topics in PV domain\, which capture influence of emerging technologies like AI\, IoT\, Big Data. Not merely that\, we have exciting surprise activities which will help you to interact more with your peers. This will be surely an exciting event wherein you could get chance to meet big industry gems. Let’s gather to shape the industry with your magnificent ideas. \n \nSPONSORS: \n\nCovance\nBrookwood Global\n\nWe also have more sponsorship opportunities available for the event\, which gives you an opportunity to sponsor/speak/exhibit/Booth/Stall and create brand awareness. In addition\, the networking opportunities in focused and relevant industry gathering provide the personal contact necessary for business development efforts. \nDELEGATE REGISTRATION: \nIn order to register please contact us on Email: kavitha@virtueinsight.co.in   \n1 Delegate @ £1299 + VAT \n3 Delegates @ £2598 + VAT \nGet more from the event\, with a broader scope bringing the whole communications value chain together. Enjoy and make the best out of our dedicated networking drinks time\, meet the leading international vendors showcasing the products of tomorrow in the co-located exhibition. Expand your knowledge of the latest business models and strategies in the high-level conference.
URL:https://www.pharmajournalist.com/event/21st-pharmacovigilance-2020/
LOCATION:Pestana Chelsea Bridge Hotel\, London\, United Kingdom
ORGANIZER;CN="Virtue Insight":MAILTO:kavitha@virtueinsight.co.in
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200303
DTEND;VALUE=DATE:20200305
DTSTAMP:20260515T051839
CREATED:20191215T130603Z
LAST-MODIFIED:20191215T130603Z
UID:23348-1583193600-1583366399@www.pharmajournalist.com
SUMMARY:Animal Microbiome & Nutritional Health Congress
DESCRIPTION:Building on the huge success of our European Animal Microbiome Congress in London this past July\, we are incredibly excited to return to the USA in March 2020\, this time in Chicago\, Illinois. \n \nInterest in animal microbiomes as therapeutics is rapidly expanding\, as techniques to study the microbial world decrease in cost and increase in accessibility\, and case studies from human medicine receive widespread attention. The current state of techniques and strategies to modify the microbiome to improve animal health\, focusing on applications in domestic pets and farm animals\, will be the main focus of this event. \nWe will be untangling the basic biology of microbiome-directed therapies in animals and the examples to date of application of probiotics\, prebiotics\, and other microbiome-directed therapies and feed additives being used to benefit animal health. We will also be looking heavily at the impact of different feed and nutrition profiles on animal microbiomes\, and the power of nutrition in affecting animal health in a beneficial way. \nFinally\, the event will host the Animal Microbiome & Nutritional Health Innovation Showcase\, where 8 emerging companies in the field of animal nutrition will present the microbiome and nutritional solutions they can bring to market. \nTo learn more about this event and to register online\, visit https://animalmicrobiomecongressusa.com/
URL:https://www.pharmajournalist.com/event/animal-microbiome-nutritional-health-congress/
LOCATION:Warwick Allerton – Chicago\, 701 N Michigan Avenue\, Chicago\, IL\, 60611\, United States
ORGANIZER;CN="Kisaco Research":MAILTO:events@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200303
DTEND;VALUE=DATE:20200306
DTSTAMP:20260515T051839
CREATED:20191215T131423Z
LAST-MODIFIED:20191215T131423Z
UID:23352-1583193600-1583452799@www.pharmajournalist.com
SUMMARY:Gene Therapy for Blood Disorders
DESCRIPTION:Discover the Clinical & Commercial Potential of Gene Therapy & Editing Approaches Revolutionizing Hemophilia\, Sickle Cell Disease & β-Thalassemia Treatment \nRevolutionary gene therapies are redefining the treatment of blood diseases. \n \nWith an approved gene therapy treatment for β-thalassemia in the EU\, and hemophilia candidates seeking 2020 approval in the USA and beyond\, pioneers in the space must overcome hurdles they have never previously encountered to transform their clinical candidates into a commercial reality. Gene Therapy for Blood Disorders will unite industry leaders across the blood disease space to delve into the specific clinical and commercial challenges faced by companies developing gene therapies for hemophilia\, sickle cell disease and\nβ-thalassemia. \nEvaluate the best strategies for a commercial launch in blood disease\, optimize your trial design\, gain insights on revolutionary novel technologies\, and ultimately enhance your current hematology gene therapy program to bring transformative treatments to patients more quickly and efficiently. \nDownload the full event guide to learn more from companies including bluebird bio\, Spark Therapeutics and Editas Medicine
URL:https://www.pharmajournalist.com/event/gene-therapy-for-blood-disorders/
LOCATION:Courtyard Boston Downtown\, 275 Tremont Street\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200304
DTEND;VALUE=DATE:20200306
DTSTAMP:20260515T051839
CREATED:20200217T092857Z
LAST-MODIFIED:20200217T093049Z
UID:24197-1583280000-1583452799@www.pharmajournalist.com
SUMMARY:8th Annual Pharma AntiCounterfeiting & Serialisation 2020
DESCRIPTION:8th Annual Pharma AntiCounterfeiting & Serialisation 2020 will provide you insight into the current state of play in the EU & US on the vital role of technology impact in the sustainability of pharma and healthcare systems. Our speakers will outline the key recent developments in technology impact in pharma and healthcare in the EU and other international jurisdictions. The event will also address some of the most achievable possibilities of integrating AI\, IoT and blockchain within pharma and healthcare through a mixture of practical\, lectures and roundtable discussions specifically designed. \nCONFERENCE SPONSORS: \n\nIO AG\n\nWe have sponsorship opportunities available for the event\, which gives you an opportunity to sponsor/speak/exhibit/stall/booth and create brand awareness. In addition\, the networking opportunities in focused and relevant industry gathering provide the personal contact necessary for business development efforts. For further details please contact Kavitha at Email: kavitha@virtueinsight.co.in \nCONFERENCE DELEGATE PRICING: \nIn order to Register as delegate for the conference please contact Kavitha at kavitha@virtueinsight.co.in \nPlease note that this is a PAID event and NOT A FREE event (no complimentary passes available). Any invite\, email or tickets issued mentioning it as a free pass or free ticket to this event through any third party site will strictly not be accepted by the organizer and entry won’t be granted at the event. \n \nEarly Bird Discount Price: \n1 Delegate @ £899 + VAT (Valid Till 24th Jan 2020) \n3 Delegates @ £1798 + VAT (Valid Till 25th Jan 2020) \nStandard Price: \n1 Delegate @ £1299 + VAT (Valid from 25th Jan 2020) \n3 Delegates @ £2598 + VAT (Valid from 25th Jan 2020) \nKEY SPEAKERS: \n\nNICHOLAS CALL\, Special Agent\, FDA\nGALIT MEYRAN\, Serialization Global Program Manager\, Teva\nMARCEL DE GRUTTER \, Project Manager Serialization – Regulatory & Government Affairs Liaison\, Abbott\nPATRIK MERCKELL\, External Business Process Analyst and Project Manager\, Roche\nEIKE HILLBRICHT \, Corporate Security Manager\, Boehringer Ingelheim\nJACK JING \, Global Business Development Director / Head of EU Commercial Operations\, Seacross Pharmaceuticals\nLEYLA HANNBECK \, CEO\, Association of Independent Multiple Pharmacies\nSULTAN DAJANI \, Pharmacist Superintendent\, Wainwrights Chemists\nTRACQ ANTOINE\, Head of Commercial Logistics & Serialization\, Galderma\nADRIAN VAN DEN HOVEN\, Director General of Medicines for Europe\, European Medicines Verification Organisation (EMVO)\nMIKE ISLES\, Executive Director\, European Alliance for Access to Safe Medicines\nMONIKA DERECQUE POIS\, Director General\, GIRP—European Healthcare Distribution Association\nBILL ARONSON \, COO\, Artificial Intelligence Research Group\nMARIE MANLEY \, Partner\, Head of the UK Life Sciences Practice\, Sidley Austin\nSANDY EISEN\, Chief Medical Officer\, Fromtline Pharma\n\nPlus many more \nKEY THEMES: \nAnti-counterfeiting\, Serialisation\, T&T \n\nShaping the future for Healthcare\nEffect of Post (FMD) Deadline\nSerialisation strategies- Choosing a Serialisation solution\nAI algorithms to crack down on fake products\nFight the FAKE – Protect the public\nTechnology Impact – Current digital world\nSerialisation and Compliance\nPenetrating the legitimate supply chain\nPackaging Techniques – Protecting your products\n\nBrexit \n\nImpact on EU\, US and Row market\n\nGet more from the event\, with a broader scope bringing the whole communications value chain together. Enjoy and make the best out of our dedicated networking drinks time\, meet the leading companies showcasing the products of tomorrow in the co-located exhibition. Expand your knowledge of the latest business models and strategies in the high-level conference.
URL:https://www.pharmajournalist.com/event/8th-annual-pharma-anticounterfeiting-serialisation-2020/
LOCATION:Pestana Chelsea Bridge Hotel\, London\, United Kingdom
ORGANIZER;CN="Virtue Insight":MAILTO:kavitha@virtueinsight.co.in
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200304
DTEND;VALUE=DATE:20200306
DTSTAMP:20260515T051839
CREATED:20200217T093608Z
LAST-MODIFIED:20200217T093608Z
UID:24207-1583280000-1583452799@www.pharmajournalist.com
SUMMARY:3rd Annual Phrama AI\, IoT & Blockchain 2020
DESCRIPTION:“Competences to Combat Counterfeits & Impact of AI\, IoT\, Blockchain & Big Data in Pharma” \nOur 3rd Annual Pharma AI\, IoT & Blockchain 2020 will provide you insight into the current state of play in the EU & US on the vital role of technology impact in the sustainability of pharma and healthcare systems. Our speakers will outline the key recent developments in technology impact in pharma and healthcare in the EU and other international jurisdictions. The event will also address some of the most achievable possibilities of integrating AI\, IoT and blockchain within pharma and healthcare through a mixture of practical\, lectures and roundtable discussions specifically designed. \nSPONSORS: \n\nio AG\nAdvanco\n\nWe have more sponsorship opportunities available for the event\, which gives you an opportunity to sponsor/speak/exhibit/stall/booth and create brand awareness. In addition\, the networking opportunities in focused and relevant industry gathering provide the personal contact necessary for business development efforts. For further details please contact Kavitha at Email: kavitha@virtueinsight.co.in \n \nCONFERENCE DELEGATE PRICING: \nPlease note that this is a PAID event and NOT A FREE event (no complimentary passes available). Any invite\, email or tickets issued mentioning it as a free pass or free ticket to this event through any third party site will strictly not be accepted by the organizer and entry won’t be granted at the event. \nIn order to Register as delegate for the conference please contact Kavitha at kavitha@virtueinsight.co.in \n1 Delegate @ £1299 + VAT \n3 Delegates @ £2598 + VAT \nKEY SPEAKERS: \n\nSTEVEN ABRAHAMSON\, Senior Director\, Product Cyber Security\, GE Healthcare\nPATRIC JARCHOW \, Head of Global Multi-Channel Strategy\, Merck KGaA\nNICLAS NILSSON \, Head of Open Innovation in Research\, LEO Pharma\nSTEVEN WILLIAMSON\, Audit Account Director\, Information Security\, GSK\nEDDIE GUZDAR \, Medical Head UK & Ireland | Physician | Venture Capital & Board Advisor – Digital Technology\, Sanofi Genzyme\nNATALIA M.MONTEIRO\, Clinical Trial Budget & Metrics Management\, Takeda Pharmaceuticals\nPINGPING NI\, Director\, Biometrics Team Lead\, AstraZeneca\nALAN HOW\, Strategy & Operations – Global Commercial\, Merck\nHUSSAIN AL MUSCATI \, Customer Engineering Lead\, Life Sciences\, Google\nMARCO GUIDOBALDI \, Sales Engineer – Healthcare & Life Sciences\, Google\nEBERHARD SCHEUER \, Chairman\, HIT Foundation\nGABOR PURMAN \, Senior Account Director\, Patient Services and Medical Education\, NexGen Healthcare Communications\nROMIKA BHOWMICK\, Senior Manager – Digital Commercial (Europe & International Markets)\, Teva\nBRAM VAN LEEUWEN \, Lead (digital) Innovation BeNeLux\, Sanofi\nEVI MATHIOU\, Legal\, Compliance & Quality Manager BA Europe East & South\, Novo Nordisk\nMYLES FURNACE\, Digital Health and Data Lead\, UK & Ireland Speciality Care\, IPSEN\nRAMESH KRISHNAMURTHY \, Strengthen international institutions\, WHO (World Health Organization)\nSIDDHI TRIVEDI \, Healthcare Innovator\, Co-founder\, Beyond Identity \nALF GOEBEL\, CEO\, Advanco\nIGNACIO H. MEDRANO\, Founder & Chief Medical Officer\, SAVANA\nEDITH LECOMTE NORRANT \, CEO & CSO\, IPSOMEDIC\nROBIN SMITH\, Security and Information Assurance Lead\, Independent Office for Police Conduct (IOPC)\n\nPlus many more \nKEY THEMES: \nAI and IoT \n\nApplications in Pharma and Healthcare\nChallenges and opportunities\nUse of AI in drug discovery\nRole of Cyber Security in age of IoT and Healthcare Hacks\nIP – Cybercrime in the pharmaceutical industry: a booming business\nTransforming the healthcare and pharmaceutical industry\n\nBlockchain \n\nHow it transforms pharma and healthcare\nBlockchain in Logistics and Supply Chain\nA must learn technology\nBlockchain technology and start-ups – where do you get started?\nApplication areas for blockchain within healthcare?\n\nBig Data \n\nPotential future in synchronicity of data\nBig data =Big impact\nA Revolution in Drug Discovery and Pharma R&D\nHow to involve patients better to develop drugs\n\nBrexit \n\nImpact on EU\, US and Row market\n\nGet more from the event\, with a broader scope bringing the whole communications value chain together. Enjoy and make the best out of our dedicated networking drinks time\, meet the leading companies showcasing the products of tomorrow in the co-located exhibition. Expand your knowledge of the latest business models and strategies in the high-level conference.
URL:https://www.pharmajournalist.com/event/3rd-annual-phrama-ai-iot-blockchain-2020/
LOCATION:Pestana Chelsea Bridge Hotel\, London\, United Kingdom
ORGANIZER;CN="Virtue Insight":MAILTO:kavitha@virtueinsight.co.in
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200310
DTEND;VALUE=DATE:20200313
DTSTAMP:20260515T051839
CREATED:20191218T094051Z
LAST-MODIFIED:20191218T094051Z
UID:23467-1583798400-1584057599@www.pharmajournalist.com
SUMMARY:Inborn Errors of Metabolism Drug Development
DESCRIPTION:Join over 80 inherited metabolic disease drug developers and KOLs to explore how the key challenges prohibiting accelerated drug development are being addressed. The inaugural Inborn Errors of Metabolism Drug Development Summit will provide a discursive platform to examine where pioneering gene therapy modalities intersect with current therapeutic options and explore how diseases can be better targeted in order to address the huge unmet medical need for rare metabolic diseases. \nWith scarce treatment options leaving inborn errors of metabolism a devastating\, unfilled and unmet medical need\, the opportunity for biopharma to do better and aggressively tap into a lucrative and life changing market of gene modalities is growing. For the first time\, the Inborn Errors of Metabolism Drug Development summit will look to examine how the experience within existing pharmacology for rare metabolic diseases can be leveraged with the drug development strategies of those pioneering gene modalities to improve efficacy\, safety and commercial viability. \nIncorporating insights from industry-leading speakers\, this conference will delve into the key patient access\, regulatory\, clinical and commercial hurdles that need to be overcome in order to address the unmet medical need of rare metabolic diseases and fulfil their full commercial potential. \nThis is your comprehensive guide to define your drug development path for 2020. Don’t miss out on your chance to network with industry leaders and be a part of the only enriched industry forum focused on accelerating the development of better effective treatments for inborn errors of metabolism. \nTo know more about Inborn Errors of Metabolism Drug Development please click here.
URL:https://www.pharmajournalist.com/event/inborn-errors-of-metabolism-drug-development/
LOCATION:Courtyard Boston Downtown/North Station\, 107 Beverly Street\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200312
DTEND;VALUE=DATE:20200314
DTSTAMP:20260515T051839
CREATED:20191031T101142Z
LAST-MODIFIED:20191031T104348Z
UID:23118-1583971200-1584143999@www.pharmajournalist.com
SUMMARY:4th Annual MarketsandMarkets Next Gen Immuno-Oncology Congress
DESCRIPTION:In the past decade\, many scientific breakthroughs have been achieved through research including success in recent years of cancer immunotherapy with monoclonal antibodies\, cancer vaccines\, adoptive cell therapy and immune-checkpoint therapy. Personalized immunotherapy with various combinations will be the next promising strategy for the future cancer treatment direction. \n \nOur 4th Annual MarketsandMarkets Next Gen Immuno-Oncology Congress to be held on 12th-13th March 2020 in London\, UK would address the challenges and future directions in IO research. The congress aims to bring academicians\, researchers and scientists from research institutes pharmaceutical\, bio-pharmaceutical and biotechnology companies to discuss the latest updates in development of ADC’s\, Bispecific Antibodies\, Cellular Therapy and Immune Checkpoint Inhibitors. This congress would also focus on various combination strategies\, pre-clinical and translational immune-oncology developments\, updates in cellular and viral therapies\, vaccines development and personalized immunotherapy. Keynote presentations\, Brainstorming Panel Discussions and Case studies will give the stakeholders an opportunity to discuss and understand the issues faced and come up with solutions. \nKey Sessions: \n\nUpdates in development of monoclonal antibodies\, ADC’s and Bispecific Ab’s\nImmune Checkpoint Inhibitors and Combinations\nPreclinical and Translational Immuno-Oncology Developments (Preclinical models for Immunecheckpoint modulators)\nBiomarkers and Cancer Vaccines\nCAR-T cell therapy\, T Cell Therapy\nTumor microenvironment\nOncolytic Viruses\nMicrobiome in Cancer Immunotherapy\n\nTo learn more about 4th Annual MarketsandMarkets Next Gen Immuno-Oncology Congress click here \n 
URL:https://www.pharmajournalist.com/event/4th-annual-marketsandmarkets-next-gen-immuno-oncology-congress/
LOCATION:ILEC Conference Center and IBIS London Earls Court\, 47 Lillie Road\, London\, SW6 1UD
ORGANIZER;CN="MarketsandMarkets Research Private Ltd.":MAILTO:shardul.oza@marketsandmarkets.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200316
DTEND;VALUE=DATE:20200318
DTSTAMP:20260515T051840
CREATED:20191101T085034Z
LAST-MODIFIED:20191101T085034Z
UID:23143-1584316800-1584489599@www.pharmajournalist.com
SUMMARY:AI in Drug Discovery Conference 2020
DESCRIPTION:Leveraging machine learning – discovery to the next level! \nSMi group presents the launch of the inaugural AI in Drug Discovery conference taking place in London on 16th-17th March 2020. \nAI-empowered machine learning technologies hold the potential of reducing drug discovery associated costs by US$ 70 billion in the upcoming 10 years. With an estimated +39% CAGR\, AI in drug discovery is leading the way into a shorter\, cheaper and more successful R&D era where compound generation is automated\, drug synthesis is predictable and undruggable diseases are finally being targeted. \nThe presence of AI in drug discovery is tangible with the majority of drug discovery scientist already working with AI-enabled platforms using machine learning and deep learning\, neural networks and natural language processing. However\, there is a long journey ahead of optimizing AI-human connections and understanding the full potential of AI-enabled tools and platforms. \n \nBENEFITS OF ATTENDING: \n\nListen to case studies form industry leader pharmaceutical and biotechnology that have already incorporated AI into their work\nExplore how Deep Learning Methods can be leveraged for compound screening\, de novo design\, multiparameter optimization/ ADME toxicity property predictions\, chemical synthesis route predictions\nDiscover strategies for overcoming data-related challenges such as lack of consistent and quality data at the heart of AI and strategies for improving data access\nDefine unique discovery approaches such as fragment-based drug discovery and network-driven drug discovery\n\nJoin us at SMi’s inaugural AI in Drug Discovery 2020 Conference and explore the latest AI-enabled approaches for lead compound screening\, multi parameter optimization\, disease modelling\, drug synthesis and design. \nTo register please visit: www.AI-indrugdiscovery.com/pharmajwl \nPLUS\, one interactive half-day post-conference workshop \nPractical application of predictive properties in drug design\, Workshop Leader: Robert Young\, Blue Burgundy Ltd. \nEarly-Bird Rates \n\nBOOK BY 29TH NOVEMBER AND SAVE £400\nBOOK BY 13TH DECEMBER AND SAVE £200\nBOOK BY 31ST JANUARY AND SAVE £100\n\n\nSOCIAL MEDIA HANDLES \nTwitter: @SMiPharm #SMiDrugdiscovery\nLinkedIn: follow our company page – search ‘SMi Pharma’
URL:https://www.pharmajournalist.com/event/ai-in-drug-discovery-conference-2020/
LOCATION:London\, United Kingdom
ORGANIZER;CN="SMi Group":MAILTO:hsidhu@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200317
DTEND;VALUE=DATE:20200319
DTSTAMP:20260515T051840
CREATED:20191215T125706Z
LAST-MODIFIED:20191215T125706Z
UID:23344-1584403200-1584575999@www.pharmajournalist.com
SUMMARY:Formulation & Delivery Series US
DESCRIPTION:Join over 250 leaders\, experts and researchers at the Formulation & Drug Delivery US Series\, connecting global pharma\, biotech and academia for high-level discussions on the latest innovations for biopharmaceutical development. \n \nThe Formulation & Drug Delivery Congress will discuss the state of the industry\, looking at new strategies for optimizing biologic formulations such as antibodies\, proteins and vaccines\, as well as highlighting key updates in amorphous solid dispersions and combination products. \nAlongside this\, The Inhalation & Respiratory Drug Delivery Congress will examine the latest developments in inhaled vaccines and antibiotics\, alongside challenges and trends in generic formulation. \nFeaturing over 55+ renowned industry speakers from leading organisations such as Merck\, Takeda and AstraZeneca\, this programme will allow you to discuss the key topics that interest you. \nView the Programme: https://bit.ly/33nCbI2 \n 2020 Live Webinars: \n‘The Design And Development Of A Connected Inhalation System To Help With Monitoring And Patient Adherence’ – Hosted by Paul Upham\, Head\, Smart Devices\, Genentech  \n“Understanding Supersaturation Of Small Molecule To Improve Oral Bioavailability”  – Hosted by Sudhakar Garad\, Global Head of Chemical and Pharmaceutical Profiling\, Novartis Institutes for BioMedical Research \n“Ocular biopharmaceutics: impact of modeling and simulation on topical ophthalmic formulation development” – Hosted by Hovik Gukasyan\, Associate Director\, Early Development Formulation and Physical Chemistry\, Allergan \nWebinar Registration:  https://bit.ly/2qvy91O \nGo Social: For the latest conference updates follow us on Twitter @FDDCongress and join the congress conversation on #FDDUS20  \nFor more information about the event\, please contact Guillaume Alonso at g.alonso@oxfordglobal.co.uk
URL:https://www.pharmajournalist.com/event/formulation-delivery-series-us/
LOCATION:Hilton San Diego Mission Valley\, 901 Camino del Rio South\, San Diego\, CA\, 92108\, United States
ORGANIZER;CN="Oxford Global":MAILTO:g.alonso@oxfordglobal.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200330
DTEND;VALUE=DATE:20200403
DTSTAMP:20260515T051840
CREATED:20191104T104106Z
LAST-MODIFIED:20191104T121228Z
UID:23228-1585526400-1585871999@www.pharmajournalist.com
SUMMARY:4th Annual Gene Therapy for Rare Disorders
DESCRIPTION:The 4th Annual Gene Therapy for Rare Disorders will focus exclusively on overcoming the late-stage commercial challenges drug developers face when delivering gene therapies to market. \nWith approvals in a number of indications over the last year\, and more rapidly approaching on the horizon\, the meeting will leverage the experience from first to market pioneers\, as well as unveiling the strategies\ndrug developers are employing to improve efficacy\, safety and commercial viability. \nIncorporating insights from 80+ industry-leading speakers\, this conference will delve into the key regulatory\, reimbursement\, clinical and manufacturing hurdles that need to be overcome to realize the commercial potential of gene therapies. \nJoin 600+ of your colleagues to accelerate the progress of the next generation of gene therapies. \nThis is your comprehensive guide to define your commercial path forward in 2020. \nTo know more about 4th Annual Gene Therapy for Rare Disorders click here.
URL:https://www.pharmajournalist.com/event/4th-annual-gene-therapy-for-rare-disorders/
LOCATION:Boston Park Plaza\, 50 Park Plaza\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200330
DTEND;VALUE=DATE:20200402
DTSTAMP:20260515T051840
CREATED:20191215T132020Z
LAST-MODIFIED:20191215T132020Z
UID:23357-1585526400-1585785599@www.pharmajournalist.com
SUMMARY:Cell Engager Summit
DESCRIPTION:The Cell Engager Summit is the only meeting focused on developing multi-specific cell engaging therapies in liquid and solid tumor indications\, accelerating early discovery innovation into the clinic. \n \nUnderstand the very latest in construct design\, immune cell biology\, tumor associated activation\, toxicity assessment\, solid tumor targeting strategies\, clinical insights and more. \nDiscover how to effectively scale complicated manufacturing of multi-specific cell engagers to reduce production costs and time whilst ensuring purity and quality of antibodies. \nWith 22+ hours of content\, 2 interactive workshops and over 5 hours of networking with key industry leaders\, this conference will focus solely on cell engaging drugs and how to tackle key clinical and commercial challenges. \nTo learn more about this event and to register online\, visit https://ter.li/hkw9b8
URL:https://www.pharmajournalist.com/event/cell-engager-summit-2020/
LOCATION:Courtyard Boston Downtown\, 275 Tremont Street\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200330
DTEND;VALUE=DATE:20200401
DTSTAMP:20260515T051840
CREATED:20191215T210012Z
LAST-MODIFIED:20200323T125422Z
UID:23453-1585526400-1585699199@www.pharmajournalist.com
SUMMARY:SMi’s 22nd Annual Superbugs & Superdrugs Conference
DESCRIPTION:A Focus on Non-traditional Approaches in the Fight against Antimicrobial Resistance \nSponsored by Scynexis \nCO-CHAIRS FOR 2020: Cara Cassino\, Chief Medical Officer\, Contrafect and Michael Dawson\, Director\, Mike Dawson Antimicrobial Research Consultancy \nAnnouncement: Due to ongoing concerns over COVID-19 this conference is now available with remote access only – please register your place at www.superbugssuperdrugs.com \nAs one of the most impactful pharmaceuticals for maintaining public health\, antibiotics have been around since early 20th century and have since shown a need for significant progress in recent years. This is mainly due to its broad and indiscriminate use which has slowly given birth to multi- to extensively-drug resistant bacteria rendering our current last-resort antibiotic arsenal\, including colistin\, carbapenems\, 3rd and 4th generation cephalosporins\, useless. \n \nThis year’s event aims to showcase a suite of sessions focused on novel drugs and approaches\, particularly highlighting non-traditional and traditional therapies that provide an innovative means to spearhead the issue. The conference will also place significant emphasis on the much-needed support for innovative approaches such as sessions tackling the funding and support and the regulation that provides guidance towards the goal of ameliorating the continued rise of anti-microbial resistance AMR. \nIt is crucial to bring industry leaders together to discuss the strategies in place that reduce AMR\, evaluate the role pharmaceutical companies and funding bodies play in reducing AMR\, learn about new diagnostics approaches to identify AMR and consider novel candidates and alternatives to anti-microbials. Join us in March 2020\, along with leaders from the pharmaceutical industry\, academia\, regulatory and funding bodies\, and public-private partnerships to discuss the way forward. #SMiBugs \nFEATURED SPEAKERS FOR 2020: \n\nYuri Gleba\, Professor\, Founder\, Nomad Bioscience\nMark Albrecht\, Branch Chief\, Antibacterials program\, BARDA/HHS\nPaul Finn\, CEO\, Oxford Drug Design\nCara Cassino\, Chief Medical Officer\, Contrafect\nMartin Everett\, CSO\, Antabio\nSamareh Lajaunias\, Director\, Combioxin SA\nFrancois Moreau\, Scientific Director\, Mutabilis\nEmma Leire\, Microbiology Lead\, Centauri Therapeutics\nLorenzo Corsini\, Co-Founder/CEO/R&D\, Phagomed\nStephen Barat\, VP\, Preclinical Research and Early Development\, Scynexis\nColm Leonard\, Consultant Clinical Adviser/Consultant Thoracic Physician/Honorary Pro \n\nWHATS ON THE AGENDA FOR 2020? \n\nDiscuss the new classes of non-antibiotic antibacterial proteins: Colicins and Colicin-like Bacteriocins from Nomad Bioscience\nGain valuable insight towards fighting severe and resistant infections through neutralising bacterial virulence effectors from Combioxin\nExamine a UK project looking at novel value assessment and reimbursement for novel antimicrobials from NICE/Manchester University NHS Foundation Trust\nExplore direct lytic agents (DLAs) and their potential as a successful disruptive anti-infective technology with Contrafect\nEvaluate the utility of machine learning and AI in antibiotic drug discovery with Oxford Drug Design\n\nTo register visit www.superbugssuperdrugs.com/PJWL \nEARLY BIRD-RATES \n\nREGISTER BY 29TH NOVEMBER AND SAVE £400http://www.pharmajournalist.com/event/smis-22nd-annual-superbugs-superdrugs-conference/Holiday Inn Kensington ForumHoliday Inn Kensington Forum\nREGISTER BY 13TH DECEMBER AND SAVE £200\nREGISTER BY 31ST JANUARY AND SAVE £100
URL:https://www.pharmajournalist.com/event/smis-22nd-annual-superbugs-superdrugs-conference/
LOCATION:Holiday Inn Kensington Forum\, 97 Cromwell Rd Kensington\, London\, SW7 4DN\, United Kingdom
ORGANIZER;CN="SMi Group Limited":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200401
DTEND;VALUE=DATE:20200403
DTSTAMP:20260515T051840
CREATED:20190906T095018Z
LAST-MODIFIED:20190906T095018Z
UID:22300-1585699200-1585871999@www.pharmajournalist.com
SUMMARY:3rd Annual Pharma Supply-Chain & Security World 2020
DESCRIPTION:The Annual Pharma Supply Chain and Security World Summit is back in London for the 3rd time\, and this time with more focus on optimizing your supply chain challenges to ensure an agile\, responsive\, streamlined and secured supply chain. Pharmaceutical companies have to resist the challenges looming from supply chain security lapses to avoid infiltration of counterfeit\, diverted\, and adulterated drugs entering into the supply chain. \nTo protect your brand and build a genuine future\, Corvus Global Events invites you to Pharma Supply Chain & Security World 2020 – Supply-chain\, Drug Serialization And Anti-Counterfeiting conference\, which will have Pharma industry experts sharing various challenges faced\, new strategies\, case studies and use of innovative ideas\, the conference will also offer opportunities to encourage partnerships and collaborations. In this conference you’ll not only discover innovative technologies\, transformation strategies and collaboration methods\, but how best to implement them to optimise your supply chain processes and strategies for drug anti-counterfeiting. \nTo learn more and to register online\, visit: http://bit.ly/2lB3X2E
URL:https://www.pharmajournalist.com/event/3rd-annual-pharma-supply-chain-security-world-2020/
ORGANIZER;CN="Corvus Global Events":MAILTO:info@corvusglobalevents.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200407
DTEND;VALUE=DATE:20200410
DTSTAMP:20260515T051840
CREATED:20200204T131833Z
LAST-MODIFIED:20200204T131833Z
UID:24006-1586217600-1586476799@www.pharmajournalist.com
SUMMARY:4th Advanced Sourcing R&D Procurement in Pharma Summit
DESCRIPTION:Join the 4th Advanced Sourcing R&D Procurement in Pharma Summit to: Discover How Can R&D Procurement Enhance SRM\, Expedite Speed-to-Market & Deliver Beyond TCO.  As the only meeting catered to the needs of senior R&D Procurement\, Sourcing and Category Management leaders\, we have seen the transformation since we launched this meeting in 2017. Over the last 3 years\, we have witnessed the industry begin to mature – procurement leaders play an increasingly important role as strategic business partner and innovation enabler\, supporting R&D to progress into clinic and commercialization. \nBe part of this growing community where you can share your common challenges and be inspired by fellow colleagues from pharma and biotech.  Find out more > https://ter.li/8mwudk
URL:https://www.pharmajournalist.com/event/4th-advanced-sourcing-rd-procurement-in-pharma-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200408
DTEND;VALUE=DATE:20200409
DTSTAMP:20260515T051840
CREATED:20200318T114724Z
LAST-MODIFIED:20200318T124952Z
UID:24662-1586304000-1586390399@www.pharmajournalist.com
SUMMARY:Temperature Controlled Logistics in Biopharmaceuticals US
DESCRIPTION:Temperature Controlled Logistics in Biopharmaceuticals US 2020 is going virtual! \nNow in its 4th year\, Temperature Controlled Logistics is going VIRTUAL to deliver key\, actionable insights into very latest regulatory requirements\, technological innovations\, strategic developments\, and how to implement them into your commercial and clinical logistics with both maximum efficiency and minimal cost. \nTemperature Controlled Logistics will bring you everything you need to ensure a successful and compliant implementation for storage and distribution. With a more interactive and hands on agenda including panel discussions; roundtables; speed networking; think tanks; mini workshops and more\, this event will create an environment where storage and distribution teams from across all sizes of manufacturer can work together to manage creative\, technical\, and regulatory demands while ensuring patients are safeguarded at all stages. \nJoin pharmaceutical\, medical device and biotechs experts to discuss new trends and opportunities and learn how to optimize temperature maintenance with the supply chain.
URL:https://www.pharmajournalist.com/event/temperature-controlled-logistics-in-biopharmaceuticals-us/
LOCATION:Virtual Event
ORGANIZER;CN="Arena International":MAILTO:kadin.luong@arena-international.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200414
DTEND;VALUE=DATE:20200418
DTSTAMP:20260515T051840
CREATED:20191105T115338Z
LAST-MODIFIED:20200407T153017Z
UID:23236-1586822400-1587167999@www.pharmajournalist.com
SUMMARY:eyeforpharma Philadelphia Virtual
DESCRIPTION:“As we self-isolate\, we must be careful not to isolate our ideas and thoughts. Ironically\, it has never been more important for our industry to share\, collaborate and inspire. For that reason\, we have not cancelled the eyeforpharma Philadelphia meeting\, but we’re moving it online. It is also now entirely free of charge to attend. I’m humbled that the speakers and supporters that were due to present are moving online with us\, and share with us a desire to ‘do what we can’ to make sure that we carry on communicating. I believe the event will be stronger than ever\, and more influential – at just the right time.” \n \nPaul Simms\, Chairman\, eyeforpharma \nWhy eyeforpharma Philadelphia Virtual is essential viewing: \n\nIt’s free for all to join: In such a difficult time\, we want to unify the industry and we’ve taken the decision to allow anyone to sign up to listen live\, ask questions and participate. If you work for a pharma or biotech\, you’ll also get access to a full meeting service so you can set up bespoke 1-1 meetings with fellow attendees.\n\n\nA speaker faculty even better than before: You’ll learn from 100+ speakers with 60+ free sessions – presentations\, panels\, fireside chats\, interactive workshops and Q&A\, You’ll also see hours of additional live and on-demand content\, including never-before-seen interviews with Kabir Nath\, President & CEO North America\, Otsuka\, Julie Gerberding\, EVP and Chief Patient Officer\, Communications\, Global Policy and Population Health\, Merck\, James Musick\, VP and Head of Digital Transformation\, Neurology\, UCB\, and many more.\n\n\nConnect with industry leaders around the world: Without the constraints of geography\, we’ll have thousands of industry leaders from across the globe coming together to network and collaborate.\n\n\nComplete virtual meetings platform: Send messages to connect 1-on-1 with your fellow attendees. Schedule meetings and use a virtual private meeting room to chat.\n\n\nFull virtual exhibition: Showcasing over 50+ exhibitors\, search for the latest services and technology solutions from your desk\, watch demo videos and the ability to share your virtual business card.\n\nRegister for FREE here: https://bit.ly/2UPFCVZ Join the conversation and become healthcare’s solution.
URL:https://www.pharmajournalist.com/event/eyeforpharma-philadelphia-virtual/
LOCATION:Online\, PA
ORGANIZER;CN="eyeforpharma":MAILTO:ksharp@eyeforpharma.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200415
DTEND;VALUE=DATE:20200418
DTSTAMP:20260515T051840
CREATED:20191215T132554Z
LAST-MODIFIED:20191215T132652Z
UID:23361-1586908800-1587167999@www.pharmajournalist.com
SUMMARY:Neuroimmunology Drug Development Summit 2020
DESCRIPTION:More and more pharma and biotech companies are investing in research focused on neuroimmunology and neuroinflammation’s relation to neurodegenerative diseases in the challenge to develop clinically effective therapeutics. \n \nThe 2nd Neuroimmunology Drug Development Summit’s agenda has specifically designed alongside neuroimmunology experts from the likes of Denali\, AbbVie and Biogen to help these drug developers to overcome their translational challenges and successfully translate their drug candidates into the clinic. \nImmerse yourself in the field’s cutting-edge scientific advances and take this unrivaled opportunity to join over 23 expert industry speakers and over 80 drug developers from the neuroimmunological community for over 7 hours of dedicated networking time and 2 deep-dive workshops. \nTo find out more and view the full speaker line-up\, download the full event guide.
URL:https://www.pharmajournalist.com/event/neuroimmunology-drug-development-summit-2020/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200420
DTEND;VALUE=DATE:20200423
DTSTAMP:20260515T051840
CREATED:20200309T093538Z
LAST-MODIFIED:20200309T093538Z
UID:24547-1587340800-1587599999@www.pharmajournalist.com
SUMMARY:2nd Digital Health  for Pharma (DH4P)
DESCRIPTION:Digital Health for Pharma (DH4P) is the leading Digital Health conference specifically developed for pharmaceutical and life science commercial organizations. Co-created by Evolution Road and ExL Events’ Digital Pharma Series teams\, the three-day event serves to educate life science organizations on how best to leverage digital tools to enhance the commercial model of health and pharma; while also educating patients and bridging the gap between knowledge and information\, pre-commercial and commercialization. \n \nFor 2020\, ExL Events and strategic partners at Evolution Road explore five core leverage models of learning: \n\nINVEST\nINCUBATE/ACCELERATE\nCOMMERCIALIZE\nCOLLABORATE\nCO-DEVELOP\n\nLearn more: http://bit.ly/2TJ2cOh
URL:https://www.pharmajournalist.com/event/2nd-digital-health-for-pharma-dh4p/
LOCATION:Philadelphia\, PA\, Philadelphia\, PA\, United States
ORGANIZER;CN="ExL Events%2C a division of Questex%2C LLC":MAILTO:awarren@questex.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200422
DTEND;VALUE=DATE:20200425
DTSTAMP:20260515T051840
CREATED:20200309T092247Z
LAST-MODIFIED:20200309T092247Z
UID:24541-1587513600-1587772799@www.pharmajournalist.com
SUMMARY:9th Digital Marketing for Medical Devices West
DESCRIPTION:Digital Marketing for Medical Devices is the premier event in the west coast for medical device companies to explore best practices and innovations to improve their digital marketing strategy. Med device companies will hear from their peers in the industry as well as marketing agencies who will reveal the most effective methods to market their products in a digital age. \n \nThe event takes place in San Francisco\, one of the largest tech hubs in the world\, as the medical device industry in this region is expanding at a rapid pace. DMMD West provides a platform to assist this rapid expansion. From innovation through research and development\, marketing and data analytics\, communication and branding strategies\, and measuring KPIs and ROIs\, this event serves to assist your organization\, small and large\, along your product life cycle. \nLearn more: http://bit.ly/39xKlke
URL:https://www.pharmajournalist.com/event/9th-digital-marketing-for-medical-devices-west/
LOCATION:San Francisco\, CA\, San Francisco\, CA\, United States
ORGANIZER;CN="ExL Events%2C a division of Questex%2C LLC":MAILTO:awarren@questex.com
END:VEVENT
END:VCALENDAR